Transformational 2024: successfully advanced from preclinical to clinical stage companyStrengthened leadership team to drive growth and advance ...

Abbott received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy (IVL) system.

Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.

Boston Scientific received FDA clearance for its Bolt intravascular lithotripsy (IVL) system, according to the FDA's 510(k) ...

Abbott (ABT) announced that the U.S. Food and Drug Administration, FDA, has approved an investigational device exemption, IDE, for its Coronary ...

Xojo has just rolled out its latest release, Xojo 2025 Release 1, and it’s packed with features that developers have been ...

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...

The investigational AeroNova® System delivers continual diaphragm neurostimulation in conjunction with mechanical ventilation and is designed to mitigate the negative effects of ventilation that ...

The AeroNova System is a novel, minimally invasive medical device designed to deliver continuous diaphragm neurostimulation in tandem with mechanical ventilation. The investigational device aims ...